Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$72.5 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","amount":"$3.8 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Therapeutics to Receive $1.0 Million Milestone Payment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Quest Products","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces Agreement For a Fundraising of Approximately $50 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Polar Capital","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Summit Announces Closing of Private Placement of $50 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Summit Therapeutics Provides Update on Ridinilazole","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for 06DX01190R

    Menu

    06DX01190R

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Summit Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Therapeutics Provides Update on Ridinilazole

              Details:

              SMT19969 (ridinilazole) is a targeted-spectrum antimicrobial that shows potential in treatment of initial C difficile infection and in providing sustained benefit through reduction in disease recurrence.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: SMT19969

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Summit Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021

              Details:

              Ridinilazole is the investigational first-in-class drug that completed enrollment of a Phase III clinical trial, Ri-CoDIFy. The primary endpoint of this trial seeks to demonstrate the superiority of ridinilazole in sustained clinical response as compared to vancomycin.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: SMT19969

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Summit Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster

              Details:

              Ridinilazole is our investigational drug currently in Phase III Ri-CoDIFy clinical trials with the goal of use as first-line therapy to treat initial infection and reduce recurrence of Clostridioides difficile infection.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: SMT19969

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Summit Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Announces Closing of Private Placement of $50 Million

              Details:

              Funds to be used for continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole; Preparatory activities to support the commercial launch of ridinilazole; Development of early-stage research projects using Discuva Platform.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Polar Capital

              Deal Size: $50.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement November 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Quest Products

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Announces Agreement For a Fundraising of Approximately $50 Million

              Details:

              Funds support continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection; launch of Ridinilazole and Development of early-stage research projects using the Company’s Discuva Platform.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $50.0 million Upfront Cash: Undisclosed

              Deal Type: Financing October 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Summit Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health

              Details:

              The data demonstrated that ridinilazole’s microbiome preservation resulted in a gut environment expected to inhibit the growth of C. difficile. In contrast, vancomycin treatment resulted in a gut environment that may more highly favor the growth of C. difficile.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: SMT19969

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Summit Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Therapeutics to Receive $1.0 Million Milestone Payment

              Details:

              The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eurofarma Laboratorios S.A

              Deal Size: $3.8 million Upfront Cash: Undisclosed

              Deal Type: Collaboration February 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Summit Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work

              Details:

              The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million.

              Lead Product(s): Ridinilazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority

              Deal Size: $72.5 million Upfront Cash: Undisclosed

              Deal Type: Funding January 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY